Waters Corporation (WAT) - Q1 2007 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2007. Waters Corporation designs, manufactures, and services analytical instrument systems, including high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC), mass spectrometry (MS), and thermal analysis instruments. The company operates through two primary divisions: the Waters Division and the TA Division.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Total Net Sales | $330.8 million | $290.2 million |
| Gross Profit | $187.5 million | $169.6 million |
| Gross Margin | 56.7% | 58.4% |
| Operating Income | $72.8 million | $59.5 million |
| Net Income | $55.9 million | $44.2 million |
| Diluted EPS | $0.54 | $0.42 |
| Operating Cash Flow | $82.7 million | $78.4 million |
| Cash and Equivalents (End of Period) | $503.7 million | $481.2 million |
| Total Debt | $855.0 million | $885.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% year-over-year, driven by new product introductions (ACQUITY UPLC, Q-Tof Premier, Synapt HDMS), increased pharmaceutical customer spending, and a full quarter of sales from 2006 acquisitions. Foreign currency translation contributed a 3% benefit.
- Segment Performance: The TA Division saw significant growth of 35%, aided by the Thermometric acquisition and new product launches. The Waters Division grew 12%.
- Margin Compression: Gross margin decreased to 56.7% from 58.4%, attributed to a higher mix of new products with higher initial manufacturing costs and unfavorable foreign currency impacts on UK-manufactured MS products.
- Restructuring: Operating income benefited from the absence of the $4.4 million restructuring charge recorded in Q1 2006. No new restructuring charges were incurred in Q1 2007.
- Debt Refinancing: In January 2007, the company entered a new credit agreement, borrowing $855 million to replace prior facilities. Total debt decreased slightly from the prior year due to repayments.
Guidance, Outlook, and Risks
- Outlook: Management expects gross profit percentages to improve later in the year as volume efficiencies are achieved on new products. Selling and administrative expenses are expected to grow at a similar rate through the remainder of 2007.
- Share Repurchases: The company completed its $500 million 2005 repurchase program and initiated a new $500 million program in February 2007. In Q1 2007, $81.5 million was spent on repurchases.
- Accounting Changes: The company adopted FIN 48 (Accounting for Uncertainty in Income Taxes) effective January 1, 2007, resulting in a $3.9 million charge to retained earnings and the classification of $63.7 million in unrecognized tax benefits as a long-term liability.
- Risks: Key risks include reliance on pharmaceutical industry capital spending (approx. 52% of sales), foreign exchange rate fluctuations (approx. 69% of sales outside the U.S.), and ongoing patent litigation with Agilent/HP regarding the Alliance pump, though management believes outcomes will not be material.
Investor Verification Checklist
- Margin Recovery: Verify if gross margins improve in subsequent quarters as management predicts volume efficiencies on new products.
- Pharma Spending: Monitor capital expenditure trends in the pharmaceutical and biotechnology sectors, which represent the majority of the customer base.
- FX Exposure: Assess the impact of the strengthening U.S. dollar on future earnings, given that nearly 70% of sales are international.
- Debt Covenants: Confirm continued compliance with the new credit agreement's leverage ratio (max 3.25:1) and interest coverage ratio (min 3.50:1).
- Share Count: Track the reduction in outstanding shares due to the active $500 million repurchase program to gauge EPS accretion.